证券之星消息，截至2026年1月12日收盘，通策医疗(600763)报收于42.34元，上涨1.61%，换手率 2.38%，成交量10.63万手，成交额4.48亿元。 该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为 52.88。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股主要指标及行业内排名如下： 通策医疗2025年三季报显示，前三季度公司主营收入22.9亿元，同比上升2.56%；归母净利润5.14亿 元，同比上升3.16%；扣非净利润5.09亿元，同 ...

来源：市场资讯 有投资者在互动平台向通策医疗提问："请问截止2026年1月10日公司的股东数是多少？" 针对上述提问，通策医疗回应称："您好，截至2026年1月10日公司股东总数为9万多。为确保所有投资 者能公平地获取信息，相关股东人数信息后续请以公司正式披露的定期报告为准，感谢您的关注。" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 ...

证券之星消息，截至2026年1月7日收盘，通策医疗(600763)报收于41.02元，下跌0.65%，换手率 1.34%，成交量5.99万手，成交额2.46亿元。 1月7日的资金流向数据方面，主力资金净流出2848.85万元，占总成交额11.56%，游资资金净流入 914.14万元，占总成交额3.71%，散户资金净流入1934.71万元，占总成交额7.85%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 通策医疗2025年三季报显示，前三季度公司主营收入22.9亿元，同比上升2.56%；归母净利润5.14亿 元，同比上升3.16%；扣非净利润5.09亿元，同比上升3.09%；其中2025年第三季度，公司单季度主营收 入8.42亿元，同比上升2.34%；单季度归母净利润1.92亿元，同比上升2.31%；单季度扣非净利润1.92亿 元，同比上升1.85%；负债率25.1%，投资收益4122.43万元，财务费用3192.82万元，毛利率41.69%。通 策医疗（600763）主营业务：医疗服务。 该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为 52.88 ...

Group 1 - The core viewpoint of the news is that Tongce Medical (600763) has shown a slight increase in stock price and has reported positive financial performance in its recent quarterly results [1][2] - As of January 6, 2026, Tongce Medical's stock closed at 41.29 yuan, with a trading volume of 79,900 hands and a total transaction amount of 329 million yuan [1] - In the recent funding flow data, the main funds experienced a net outflow of 9.82 million yuan, while retail investors saw a net inflow of 10.79 million yuan, indicating a mixed sentiment among different investor groups [1] Group 2 - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2] - The company's third-quarter results showed a single-quarter main revenue of 842 million yuan, reflecting a year-on-year increase of 2.34%, and a net profit of 192 million yuan, up 2.31% year-on-year [2] - The company has a debt ratio of 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, while maintaining a gross profit margin of 41.69% [2]

该股主要指标及行业内排名如下： 证券之星消息，截至2026年1月5日收盘，通策医疗(600763)报收于41.14元，上涨2.31%，换手率 1.75%，成交量7.81万手，成交额3.19亿元。 1月5日的资金流向数据方面，主力资金净流出3346.42万元，占总成交额10.49%，游资资金净流入 1248.28万元，占总成交额3.91%，散户资金净流入2098.15万元，占总成交额6.58%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-05 | 41.14 | 2.31% | -3346.42万 | -10.49% | 1248.28万 | 3.91% | 2098.15万 | - 6.58% | | 2025-12-31 | 40.21 | -0.30% | -630.53万 | -3.86% | 285.32万 | 1.75% | 345.21万 | 2.11% | | ...

Core Insights - The medical services sector experienced a significant increase of 4.77% on January 5, with Sanbo Brain Science leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] Medical Services Sector Performance - Sanbo Brain Science (301293) closed at 70.78, with a rise of 20.01% and a trading volume of 106,700 shares, amounting to a transaction value of 755 million [1] - Likang Life (300143) saw a closing price of 11.38, increasing by 15.18% with a trading volume of 473,200 shares, totaling 518 million [1] - Chengdu Xian Dao (688222) closed at 26.14, up 11.47%, with a trading volume of 277,100 shares, resulting in a transaction value of 704 million [1] - Other notable performers include She Nei Medical (301060) at 10.20 (+10.27%), International Medical (000516) at 4.72 (+10.02%), and Zhaoyan New Drug (603127) at 38.51 (+10.00%) [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.028 billion from institutional investors, while retail investors contributed a net inflow of 174 million [2] - Notable net inflows from institutional investors include Zhaoyan New Drug (603127) with 235 million and Sanbo Brain Science (301293) with 214 million [3] - Conversely, retail investors showed significant outflows from several stocks, including Sanbo Brain Science (301293) with a net outflow of 136 million and Likang Life (300143) with 27.9 million [3]

Core Insights - The health service industry aims to create a favorable organizational environment by providing safe, effective, convenient, and affordable basic medical and public health services to meet various health needs of residents. The demand for health-related products and services is rapidly increasing due to social progress and changes in lifestyle [1][7]. Industry Overview - The health service industry encompasses medical services, health management, health insurance, and related services, involving pharmaceuticals, medical devices, health products, and fitness products [4]. - The industry has experienced rapid growth in China, with the market size increasing from 6.37 trillion yuan in 2018 to an expected 9.55 trillion yuan by 2024, representing a compound annual growth rate of 6.98%. The "Healthy China 2030" plan projects the total market size to reach 16 trillion yuan by 2030, indicating significant growth potential [1][8]. Development History - The development of China's health service industry can be divided into four stages: 1. 1949-1990: Health check-ups were primarily hospital services focused on disease detection rather than prevention. 2. 1991-2000: Independent health check-up service institutions began to emerge in cities like Beijing. 3. 2001-2010: The introduction of Western health service concepts and rapid market demand growth led to the fast development of health service institutions. 4. 2011-present: Increased focus on medical information technology and service upgrades has improved the capabilities of health service institutions [4][5]. Relevant Policies - Recent government policies aim to optimize resource allocation, enhance preventive interventions, and improve service accessibility, which helps control the rapid growth of medical costs and reduce the disease burden on families and society. For instance, the National Health Commission issued a notice in February 2025 to address public health concerns and improve service efficiency [6]. Industry Structure and Key Companies - The operational models of health service institutions in China are diverse, including: 1. Hospital-based models leveraging brand and client resources. 2. Independent medical models with self-owned brands and facilities. 3. Health management models centered on health check-ups. 4. Comprehensive information platform models connecting online and offline services [8]. - Major companies in the health service industry include: - Meinian Health Industry Holdings Co., Ltd. - Tongce Medical Co., Ltd. - Ruici Medical Service Holdings Co., Ltd. - Ciming Health Checkup Management Group Co., Ltd. - Aikang Guobin Health Checkup Management Group Co., Ltd. [2][3][9]. Trends in Health Services - The future of health services will focus on personalized and precise care, moving from a "one-size-fits-all" approach to individualized health management based on personal data [11]. - Service delivery will become decentralized, extending beyond traditional healthcare facilities to community and home settings, enhancing accessibility and convenience [12]. - Payment models will evolve from fee-for-service to value-based care, with insurance companies and service providers collaborating to create innovative health products [13].

证券之星消息，截至2025年12月29日收盘，通策医疗(600763)报收于40.55元，下跌0.93%，换手率 0.95%，成交量4.27万手，成交额1.73亿元。 12月29日的资金流向数据方面，主力资金净流出1918.41万元，占总成交额11.06%，游资资金净流入 747.45万元，占总成交额4.31%，散户资金净流入1170.96万元，占总成交额6.75%。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股主要指标及行业内排名如下： 通策医疗2025年三季报显示，前三季度公司主营收入22.9亿 ...

| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-26 | 40.93 0.17% | | -2139.93万 | -13.49% | -693.58万 | -4.37% | 2833.51万 | - 17.86% | | 2025-12-25 | 40.86 | -0.39% | -1366.25万 | -9.81% | 697.95万 | 5.01% | 668.30万 | 4.80% | | 2025-12-24 | 41.02 0.84% | | -865.51万 | -6.83% | -135.55万 | -1.07% | 1001.06万 | 7.90% | | 2025-12-23 | 40.68 -0.83% | | -1464.22万 | -11.77% | -849.09万 | -6.82% | 2313.31万 | 18.59% | | 2025-12-22 | 41.02 -0.70% ...

从资金流向上来看，当日医疗服务板块主力资金净流出8.24亿元，游资资金净流入4129.99万元，散户资 金净流入7.83亿元。医疗服务板块个股资金流向见下表： 证券之星消息，12月26日医疗服务板块较上一交易日下跌0.21%，皓元医药领跌。当日上证指数报收于 3963.68，上涨0.1%。深证成指报收于13603.89，上涨0.54%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600721 | 自花医药 | 12.24 | 5.88% | 48.95万 | | 5.94亿 | | 301096 | 百诚医药 | 55.93 | 3.79% | 5.12万 | | 2.84亿 | | 000504 | *ST生物 | 9.20 | 3.25% | 2.70万 | | 2461.38万 | | 301201 | 诚达药业 | 41.95 | 0.84% | 6.37万 | | 2.72亿 | | 603259 | 药明康德 | 92.70 | 0. ...